Yuri Nikolsky

Yuri Nikolsky is a seasoned professional with extensive experience in the life sciences industry, spanning both business and research. Here's an overview of his career and background:

Education and Early Career

Yuri Nikolsky holds a Ph.D. in molecular genetics from Moscow State University in Russia and an MBA in finance from the Booth School of Business at the University of Chicago.12 His academic background combines expertise in both scientific research and business management.

Professional Experience

Dr. Nikolsky has over 20 years of experience in the life sciences sector. His career has included several notable positions:

Chief Scientific Officer at Zyfra Company:: He held this role from October 2017 to February 2019.4

CEO of MiLaboratory:: Nikolsky served as the CEO of MiLaboratory, a company specializing in immunosequencing and bioinformatics, from 2018 to 2021.32

VP R&D at Thomson Reuters:: Following the acquisition of GeneGo by Thomson Reuters in 2010, Nikolsky became the Vice President of Research & Development.1

CEO of GeneGo:: Prior to its acquisition, Nikolsky was the CEO of GeneGo, a systems biology company.1

CEO of ChemDiv:: He held the position of CEO at ChemDiv, a drug discovery CRO based in San Diego, CA.1

Co-founder of Integrated Genomics, Inc.:: Nikolsky co-founded this comparative genomics and bioinformatics company in Chicago, IL.1

Current Roles and Interests

As of the most recent information available:

• CEO of Prosapia Genetics5
• Associated with George Mason University's School of Systems Biology since October 20146

Research and Expertise

Dr. Nikolsky's research interests focus on disease research, personalized medicine, and translational medicine.1 He has authored over 70 research articles and holds 4 patents.1 His expertise extends to areas such as bioinformatics, systems biology, and immunosequencing, particularly in the context of vaccine research and immuno-oncology.2

Yuri Nikolsky's diverse experience in both academic research and business leadership positions him as a prominent figure in the biotechnology and life sciences industries.